Matrix metalloproteinase-2 predicts mortality in patients with acute coronary syndrome

Clinical Science

Volumn 118, Issue 4, 2010, Pages 249-257

  Dhillon, Onkar S ^a   Khan, Sohail Q ^a   Narayan, Hafid K ^a   Ng, Kelvin H ^a   Mohammed, Noor ^a   Quinn, Paulene A ^a   Squire, Iain B ^a   Davies, Joan E ^a   Ng, Leong L ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Acute coronary syndrome; Matrix metalloproteinase (MMP); Myocardial infarction; N terminal B type natriuretic peptide(NT proBNP); Prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GELATINASE B; GLUCOSE; STROMELYSIN; TROPONIN I;

ACUTE CORONARY SYNDROME; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CLINICAL ENZYME TESTS; ENGLAND; FEMALE; HEART FAILURE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PATIENT READMISSION; PEPTIDE FRAGMENTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 70549092057     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20090226     Document Type: Article

References (36)

1. Creemers, E. E., Cleutjens, J. P., Smits, J. F. and Daemen, M. J. (2001) Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ. Res. 89, 201-210
2. Kai, H., Ikeda, H., Yasukawa, H., Kai, M., Seki, Y., Kuwahara, F., Ueno, T., Sugi, K. and Imaizumi, T. (1998) Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 32, 368-372
3. Dollery, C. M. and Libby, P. (2006) Atherosclerosis and proteinase activation. Cardiovasc. Res. 69, 625-635
4. Tao, Z., Cavasin, M. A., Yang, F., Liu, Y. and Yang, X. (2004) Temporal changes in matrix metalloproteinase expression and inflammatory response associated with cardiac rupture after myocardial infarction in mice. Life Sci. 74, 1561-1572
5. Pfeffer, M. A. and Braunwald, E. (1990) Ventricular remodelling after myocardial infarction. Experimental observations and clinical implications. Circulation 81, 1161-1172
6. Rohde, L. E., Ducharme, A., Arroyo, L. H., Aikawa, M., Sukhova, G. H., Lopez-Anaya, A., McLure, K. F., Mitchell, P. G., Libby, P. and Lee, R. T. (1999) Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 99, 3063-3070
7. Heymans, S., Luttan, A., Nuyens, D., Theilmeier, G., Creemers, E., Moons, L., Dyspersin, G. D., Cleutjens, J. P. M., Shipley, M., Angellilo, A. et al. (1999) Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat. Med. 5, 1135-1142
8. Hayashidani, S., Tsutsui, H., Ikeuchi, M., Shiomi, T., Matsusaka, H., Kubota, T., Imanaka-Yoshida, K., Itoh, T. and Takeshita, A. (2003) Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 285, H1229-H1235
9. Matsumura, S., Iwanaga, S., Mochizuki, S., Okamoto, H., Ogawa, S. and Okada, Y. (2005) Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J. Clin. Invest. 115, 599-609
10. van den Borne, S. W., Cleutjens, J. P., Hanemaaijer, R., Creemers, E. E., Smits, J. F., Daemen, M. J. and Blankesteijn, W. M. (2009) Increased matrix metalloproteinase-8 and -9 activity in patients with infarct rupture after myocardial infarction. Cardiovasc. Pathol. 18, 37-43
11. Kelly, D., Cockerill, G., Ng, L. L., Thompson, M., Khan, S., Samani, N. J. and Squire, I. B. (2007) Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur. Heart J. 28, 711-718
12. Kelly, D., Khan, S., Cockerill, G., Ng, L. L., Thompson, M., Samani, N. J. and Squire, I. B. (2008) Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction. Eur. J. Heart Failure 10, 133-139
13. Squire, I. B., Evans, J., Ng, L. L., Loftus, I. M. and Thompson, M. M. (2004) Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J. Card. Failure 10, 328-333
14. Yan, A. T., Yan, R. T., Spinale, F. G., Afzal, R., Gunasinghe, H. R., Arnold, M., Demers, C., McKelvie, R. S. and Liu, P. P. (2006) Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure. J. Card. Failure 12, 514-519
15. Yan, A. T., Yan, R. T., Spinale, F. G., Afzal, R., Gunasinghe, H. R., Stroud, R., McKelvie, R. S. and Liu, P. P. (2008) Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failure. Eur. J. Heart Failure 10, 125-128
16. Tziakas, D. N., Chalikias, G. K., Hatzinikoaou, E. I., Stakos, D. A., Tentes, I. K., Kortsaris, A., Hatseras, D. I. and Kaski, J. C. (2005) N-terminal pro-B type natriuretic peptide and matrix metalloproteinases in early and late left ventricular remodelling after acute myocardial infarction. Am. J. Cardiol. 96, 31-34
17. Newby, A. C. (2006) Do metalloproteinases destabilize vulnerable atherosclerotic plaques? Curr. Opin. Lipidol. 17, 556-561
18. Higo, S., Uematsu, M., Yamagishi, M., Ishibashi-Ueda, H., Awata, M., Morozumi, T., Ohara, T., Nanto, S. and Nagata, S. (2005) Elevation of plasma matrix metalloproteinase-9 in the culprit coronary artery in patients with acute myocardial infarction: clinical evidence from distal protection. Circ. J. 69, 1180-1185
19. Ye, S. (2006) Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc. Res. 69, 636-645
20. Wu, T. C., Leu, H. B., Lin, W. T., Lin, C. P., Lin, S. J. and Chen, J. W. (2005) Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease. Eur. J. Clin. Invest. 35, 537-545
21. Blankenberg, S., Rupprecht, H. J., Poirier, O., Bickel, C., Smieja, M., Hafner, G., Meyer, J., Cambien, F. and Tiret, L. (2003) Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107, 1579-1585
22. George, J., Patal, S., Wexler, D., Roth, A., Sheps, D. and Keren, G. (2005) Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9 or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am. Heart J. 150, 484-487
23. Wagner, D. R., Delagardelle, C., Ernens, I., Rouy, D., Vaillant, M. and Beissel, J. (2006) Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. J. Card. Failure 12, 66-71
24. Richards, A. M., Nicholls, M. G., Yandle, T. G., Frampton, C., Espiner, E. A., Turner, J. G., Buttimore, R. C., Lainchbury, J. G., Elliott, J. M., Ikram, H. et al. (1998) Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 97, 1921-1929
25. Talwar, S., Squire, I. B., Downie, P. F., McCullough, A. M., Campton, M. C., Davies, J. E., Barnett, D. B. and Ng, L. L. (2000) Profile of plasma N-terminal proBNP following acute myocardial infarction: correlation with left ventricular systolic dysfunction. Eur. Heart J. 21, 1514-1521
26. Thygesen, K., Alpert, J. S. and White, H. D. (2007) Universal definition of myocardial infarction. Circulation 116, 2634-2653
27. Smilde, T. D., van Veldhuisen, D. J., Navis, G., Voors, A. A. and Hillege, H. L. (2006) Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation 114, 1572-1580
28. Eagle, K. A., Lim, M. J., Dabbous, O. H., Pieper, K. S., Goldberg, R. J., Van de Werf, F., Goodman, S. G., Granger, C. B., Steg, P. G., Gore, J. M. et al. (2004) A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month post discharge death in an international registry. JAMA, J. Am. Med. Assoc. 291, 2727-2733
29. Granger, C. B., Goldberg, R. J., Dabbous, O., Pieper, K. S., Eagle, K. A., Cannon, C. P., Van de Werf, F., Avezum, A., Goodman, S. G., Flather, M. D. et al. (2003) Predictors of hospital mortality in the Global Registry of Acute Coronary Events. Arch. Intern. Med. 163, 2345-2353
30. Omland, T., Persson, A., Ng, L., O'Brien, R., Karlsson, T., Herlitz, J., Hartford, M. and Caidahl, K. (2002) N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 106, 2913-2918
31. Factor, S. M., Robinson, T. F., Dominitz, R. and Cho, S. H. (1987) Alterations of the myocardial skeletal framework in acute myocardial infarction with and without ventricular rupture. A preliminary report. Am. J. Cardiovasc. Pathol. 1, 91-97
32. Morita, H., Khanal, S., Rastogi, S., Suzuki, G., Imai, M., Todor, A., Sharov, V. G., Goldstein, S., O'Neill, T. P. and Sabbah, H. N. (2006) Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodelling in dogs with chronic heart failure. Am. J. Physiol. Heart Circ. Physiol. 290, H2522-H2527
33. Hlatky, M. A., Ashley, E., Quertermous, T., Boothroyd, D. B., Ridker, P., Southwick, A., Myers, R. M., Iribarren, C., Fortmann, S. P. and Go, A. S. (2007) Matrix metalloproteinase circulating levels, genetic polymorphism, and susceptibility to acute myocardial infarction among patients with coronary artery disease. Am. Heart J. 154, 1043-1051
34. Levy, D., Larson, M. G., Sawyer, D. B., Siwik, D. A., Colucci, W. S., Sutherland, P., Wilson, P. W. and Vasan, R. S. (2004) Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 109, 2850-2856
35. Tayebjee, M. H., Lip, G. Y., Tan, K. T., Patel, J. V., Hughes, E. A. and MacFadyen, R. J. (2005) Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. Am. J. Cardiol. 96, 339-345
36. Cavusoglu, E., Ruwende, C., Chopra, V., Yanamadala, S., Eng, C., Clark, L. T., Pinsky, D. J. and Marmur, J. D. (2006) Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction. Am. Heart J. 151, 1101.e1-1101.e8